Radiation therapy

Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

Retrieved on: 
Wednesday, February 21, 2024

SYDNEY, Feb. 21, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specializing in oncology, today announced the early conclusion based on positive safety and promising clinical response findings observed to date of an important two-part Phase I trial. This investigator-initiated trial evaluated the use of paxalisib (an oral PI3K/mTOR dual inhibitor) with radiation therapy for the treatment of patients with PI3K pathway mutation brain metastases from solid tumors.

Key Points: 
  • SYDNEY, Feb. 21, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specializing in oncology, today announced the early conclusion based on positive safety and promising clinical response findings observed to date of an important two-part Phase I trial.
  • After reviewing the Part II patient data generated to date, the three lead investigators have determined that the primary endpoint of the study has been reached.
  • In addition, the investigators continued to observe encouraging signs of clinical response in patients in the expansion cohort.
  • The increasing incidence of brain metastasis and the low response rates to existing treatments underscores the need for new treatment options.

DiaCarta's RadTox™ Test to Monitor Tumor Response Receives Medicare Coverage

Retrieved on: 
Tuesday, February 20, 2024

This innovative approach enables physicians to assess tumor response in real-time, providing critical insights into treatment efficacy.

Key Points: 
  • This innovative approach enables physicians to assess tumor response in real-time, providing critical insights into treatment efficacy.
  • Unlike traditional molecular residual disease (MRD) monitoring, which focuses on specific tumor mutant clones post-treatment, RadTox™ offers a broader perspective.
  • "RadTox™ fills a crucial gap by offering a personalized biomarker that correlates with cell death, providing timely insights into patients' response to tumor treatments."
  • "Our initial findings across 22 tumor types with over 250,000 samples performed globally demonstrates the immense potential of this pan-cancer monitoring test."

Medical Journal: Image-Guided Superficial Radiation Therapy Is Superior to Superficial Radiation Therapy Without Guidance

Retrieved on: 
Tuesday, February 20, 2024

BURR RIDGE, Ill., Feb. 20, 2024 /PRNewswire/ -- SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT or IGSRT) for the treatment of nonmelanoma skin cancer, presented to dermatology patients as the GentleCure™ experience, announced the publication of research, "Image guidance improves freedom from recurrence in superficial radiation therapy for non-melanoma skin cancer," in Advances in Radiation Oncology, a peer-reviewed journal from the American Society for Radiation Oncology (ASTRO).

Key Points: 
  • It shows definitively that the new technology is superior, and represents a seminal moment in the care of skin cancer patients using radiation.
  • This study is the first to rigorously compare SRT to IGSRT, and it covers all the data that exists on IGSRT.
  • Superficial radiation therapy was developed over 100 years ago ( here ) and was the standard therapy for nonmelanoma skin cancer until Mohs micrographic surgery emerged in the 1930's ( here ).
  • IGSRT and the GentleCure experience will be showcased at the upcoming American Academy of Dermatology annual meeting in San Diego, at booth 3555.

MemorialCare's Vice President of Clinical Integration Shines Bright in Modern Healthcare's 40 Under 40

Retrieved on: 
Monday, February 12, 2024

FOUNTAIN VALLEY, Calif., Feb. 12, 2024 /PRNewswire/ -- MemorialCare is proud to announce that Elizabeth "Liz" Acord, vice president of clinical integration, for MemorialCare Cancer Institute was recognized by Modern Healthcare as one of its 40 Under 40 for 2024.

Key Points: 
  • FOUNTAIN VALLEY, Calif., Feb. 12, 2024 /PRNewswire/ -- MemorialCare is proud to announce that Elizabeth "Liz" Acord, vice president of clinical integration, for MemorialCare Cancer Institute was recognized by Modern Healthcare as one of its 40 Under 40 for 2024.
  • Modern Healthcare's 40 Under 40 recognizes the health care industry's rising stars age 40 and under who contribute to a culture of innovation and help their organizations achieve and exceed financial, operational, and clinical goals.
  • As vice president of clinical integration at MemorialCare, Acord oversees the system-wide cancer program and spearheads clinical research initiatives.
  • She brings extensive experience building hospital departments, developing innovative programs, and fostering collaboration between health care stakeholders.

Prevencio and Emory Winship Cancer Institute AI-driven HART CVE Test Data Predicts Risk of Adverse Cardiovascular Effects Associated with Prostate Cancer Therapy

Retrieved on: 
Wednesday, February 7, 2024

Researchers and clinicians from Emory Winship Cancer Institute collaborated to test their prostate cancer population.

Key Points: 
  • Researchers and clinicians from Emory Winship Cancer Institute collaborated to test their prostate cancer population.
  • “With cancer patients living longer, understanding the adverse cardiac effects due to cancer treatments, such as androgen deprivation therapy (ADT), is critical,” said Sagar Anil Patel, M.D., Assistant Professor, Department of Radiation Oncology and member of the Cancer and Control Research Program at Emory Winship Cancer Institute.
  • “It is rewarding to work with Dr. Patel and his team at Emory Winship Cancer Institute to demonstrate HART CVE’s usefulness in monitoring their prostate cancer patients.”
    This data adds to Prevencio’s previous HART CVE risk scoring collaboration with Memorial Sloan Kettering on lung radiation cancer patients.
  • Prostate cancer is the second most common cancer in men in the U.S., after skin cancer.

Korea University Researchers Unveil Benefits of Perioperative Radiotherapy for Treating Liver Cancer with High Recurrence Risk

Retrieved on: 
Wednesday, February 7, 2024

SEOUL, South Korea, Feb. 7, 2024 /PRNewswire/ -- More than two-thirds of patients with hepatocellular carcinoma (HCC), who receive surgical interventions, experience recurrence owing to lack of an established perioperative treatment. Now, researchers from Korea University have performed a meta-analysis to examine the oncological benefits of administering radiotherapy before or after surgery. The findings suggest that perioperative radiotherapy decreases the chances of recurrence in patients, improving their survival rate.

Key Points: 
  • Researchers have found that radiotherapy during liver cancer surgery reduces chances of recurrence and boosts survival for high-risk patients.
  • Now, researchers from Korea University have performed a meta-analysis to examine the oncological benefits of administering radiotherapy before or after surgery.
  • The findings suggest that perioperative radiotherapy decreases the chances of recurrence in patients, improving their survival rate.
  • This emphasizes the need for an adjuvant treatment like radiotherapy along with surgery for treating HCC patients with a high risk of recurrence.

Sensus Healthcare Collaborates with CureRays to Provide Oversight to Help Customers Assure Patient Safety, Reliability of Outcomes and Conformance with Regulatory Requirements

Retrieved on: 
Tuesday, February 6, 2024

BOCA RATON, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces a new multi-faceted collaboration with CureRays, a radiation oncology specialist organization based in Atlanta and Grass Valley, Calif. 

Key Points: 
  • Under the collaboration, CureRays will provide Sensus’ dermatology customers with oversight and supervision to assure patient safety, quality, reliability of outcomes and conformance with regulatory requirements, in particular in states where regulations covering the use of ionizing radiation have been tightened.
  • In addition, CureRays will research new indications for Sensus’ superficial radiotherapy (SRT and IG-SRT), including inflammatory diseases.
  • We were anxious to help stem fatalities in any way we could, and we’ve been impressed with their commitment to patient care.
  • My goal is also to help further enhance patient selection against the risks and benefits of radiotherapy.”

Beckman Coulter Diagnostics Appoints Kevin O'Reilly as New President

Retrieved on: 
Tuesday, February 6, 2024

BREA, Calif., Feb. 6, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced Kevin O'Reilly's appointment as its new president succeeding Julie Sawyer Montgomery, who is now vice president and group executive, Danaher Diagnostics.

Key Points: 
  • BREA, Calif., Feb. 6, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced Kevin O'Reilly's appointment as its new president succeeding Julie Sawyer Montgomery, who is now vice president and group executive, Danaher Diagnostics.
  • "Kevin brings more than 30 years of leadership experience, including accelerating and delivering innovation on a global scale within the healthcare industry," said Sawyer Montgomery.
  • Kevin's experience running a complex operating division as president, coupled with his track record of achieving results equips him well to lead Beckman Coulter Diagnostics' next chapter."
  • "Every hour around the world, more than a million clinical samples – representing up to a million people – are analyzed using Beckman Coulter Diagnostics platforms," said O'Reilly.

THERYQ and Gustave Roussy have been selected as part of the "i-Démo" France 2030 call for projects, operated on behalf of the French government by Bpifrance, for the "FLASHDEEP" project, for an amount of 38 million euros

Retrieved on: 
Friday, February 2, 2024

FLASHDEEP will be the world's first FLASH radiotherapy device using very high-energy electrons (VHEE; > 100 MeV).

Key Points: 
  • FLASHDEEP will be the world's first FLASH radiotherapy device using very high-energy electrons (VHEE; > 100 MeV).
  • The particle acceleration technology developed by THERYQ stems from research initiated by the European Organization for Nuclear Research (CERN) and the University Hospital of Lausanne (CHUV).
  • The first clinical FLASHDEEP device will be installed in France, at Gustave Roussy, late 2026, to conduct clinical trials with eligible patients.
  • Ultimately, it will lead to the revival of a French radiotherapy industrial sector, a field that has been neglected since the late 1980s.

INTEGRATED ONCOLOGY NETWORK and IMPERIAL VALLEY RADIATION ONCOLOGY WELCOME RADIATION ONCOLOGIST DR. YUJI SEO TO THEIR MEDICAL TEAM

Retrieved on: 
Thursday, February 1, 2024

NASHVILLE, Tenn., Feb. 1, 2024 /PRNewswire/ -- Integrated Oncology Network (ION), with Imperial Valley Radiation Oncology, is proud to announce the addition of Radiation Oncologist Dr. Yuji Seo to our medical team in California. 

Key Points: 
  • NASHVILLE, Tenn., Feb. 1, 2024 /PRNewswire/ -- Integrated Oncology Network (ION), with Imperial Valley Radiation Oncology, is proud to announce the addition of Radiation Oncologist Dr. Yuji Seo to our medical team in California.
  • Welcoming experienced, dedicated Radiation Oncologist, Dr. Yuji Seo to the Imperial Valley Region!
  • Dr. Seo is looking forward to joining the team and providing full-time radiation oncology services to the community stating, "I'm excited to join ION and Imperial Valley Radiation Oncology.
  • Contact Imperial Valley Radiation Oncology to learn more about his services.